Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSPNASDAQ:EDITNASDAQ:NTLANYSE:NVSNASDAQ:REGNNASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$41.51+0.4%$37.75$30.04▼$63.68$3.58B1.751.75 million shs1.04 million shsEDITEditas Medicine$2.12+7.6%$1.56$0.91▼$6.05$176.22M2.12.57 million shs1.49 million shsNTLAIntellia Therapeutics$8.88+6.9%$8.09$5.90▼$28.18$916.30M2.142.82 million shs2.99 million shsNVSNovartis$118.53-0.8%$111.84$96.06▼$120.92$250.57B0.591.58 million shs695,012 shsREGNRegeneron Pharmaceuticals$531.09+0.3%$563.19$476.49▼$1,211.20$57.32B0.31878,240 shs576,801 shsVRTXVertex Pharmaceuticals$450.37-1.1%$462.54$377.85▼$519.88$115.68B0.411.42 million shs445,583 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics0.00%-1.19%+6.68%-3.41%-34.93%EDITEditas Medicine0.00%+3.14%+30.46%+39.72%-61.07%NTLAIntellia Therapeutics0.00%+2.72%-2.24%-13.26%-66.96%NVSNovartis0.00%+1.12%+8.92%+6.33%+12.88%REGNRegeneron Pharmaceuticals0.00%+7.30%-10.95%-21.99%-48.94%VRTXVertex Pharmaceuticals0.00%+1.10%+3.83%-11.35%-5.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRSPCRISPR Therapeutics3.3047 of 5 stars4.32.00.00.02.82.50.6EDITEditas Medicine4.234 of 5 stars3.12.00.04.22.82.51.3NTLAIntellia Therapeutics4.5955 of 5 stars4.31.00.04.72.72.51.3NVSNovartis1.8313 of 5 stars1.04.02.50.02.80.01.9REGNRegeneron Pharmaceuticals4.8458 of 5 stars4.44.01.72.32.81.71.9VRTXVertex Pharmaceuticals4.5751 of 5 stars3.35.00.03.33.02.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.50Moderate Buy$71.7572.85% UpsideEDITEditas Medicine 2.29Hold$5.36153.00% UpsideNTLAIntellia Therapeutics 2.67Moderate Buy$34.95293.58% UpsideNVSNovartis 2.00Hold$123.384.09% UpsideREGNRegeneron Pharmaceuticals 2.85Moderate Buy$836.4857.50% UpsideVRTXVertex Pharmaceuticals 2.57Moderate Buy$515.0414.36% UpsideCurrent Analyst Ratings BreakdownLatest EDIT, NTLA, VRTX, CRSP, NVS, and REGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$7.006/16/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/9/2025REGNRegeneron PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$950.00 ➝ $800.006/5/2025REGNRegeneron PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$633.00 ➝ $560.006/3/2025NTLAIntellia TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $54.006/2/2025REGNRegeneron PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$700.00 ➝ $650.006/2/2025REGNRegeneron PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$800.00 ➝ $600.006/2/2025REGNRegeneron PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$958.00 ➝ $755.005/30/2025REGNRegeneron PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/30/2025REGNRegeneron PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold$662.005/30/2025REGNRegeneron PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$700.00 ➝ $580.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$35M102.43N/AN/A$22.52 per share1.84EDITEditas Medicine$35.84M4.95N/AN/A$4.27 per share0.50NTLAIntellia Therapeutics$45.57M20.19N/AN/A$11.73 per share0.76NVSNovartis$53.22B4.70$11.82 per share10.03$21.59 per share5.49REGNRegeneron Pharmaceuticals$14.09B4.07$34.87 per share15.23$268.50 per share1.98VRTXVertex Pharmaceuticals$11.10B10.42N/AN/A$63.90 per share7.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$4.52N/AN/AN/A-981.54%-18.46%-15.79%8/4/2025 (Estimated)EDITEditas Medicine-$153.22M-$3.04N/AN/AN/A-340.96%-80.13%-50.99%8/6/2025 (Estimated)NTLAIntellia Therapeutics-$481.19M-$5.23N/AN/AN/AN/A-49.34%-40.27%8/14/2025 (Estimated)NVSNovartis$11.94B$6.4020.1713.451.7023.56%37.24%15.85%7/17/2025 (Estimated)REGNRegeneron Pharmaceuticals$4.41B$39.2813.8713.972.3431.07%16.32%12.76%7/30/2025 (Estimated)VRTXVertex Pharmaceuticals-$535.60M-$3.92N/A25.722.11-4.86%-2.02%-1.49%7/30/2025 (Estimated)Latest EDIT, NTLA, VRTX, CRSP, NVS, and REGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million5/6/2025Q1 2025CRSPCRISPR Therapeutics-$1.27-$1.58-$0.31-$1.58N/AN/A5/5/2025Q1 2025VRTXVertex Pharmaceuticals$4.29$4.06-$0.23$2.49$2.85 billion$2.77 billion4/29/2025Q1 2025NVSNovartis$2.12$2.28+$0.16$1.83$12.92 billion$13.23 billion4/29/2025Q1 2025REGNRegeneron Pharmaceuticals$8.83$8.22-$0.61$7.27$3.40 billion$3.03 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ANVSNovartis$2.592.19%N/A40.47%N/AREGNRegeneron Pharmaceuticals$3.520.66%N/A8.96%N/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ALatest EDIT, NTLA, VRTX, CRSP, NVS, and REGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/20/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.6%5/20/20255/20/20256/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A22.0722.07EDITEditas MedicineN/A3.753.75NTLAIntellia TherapeuticsN/A6.736.73NVSNovartis0.481.040.84REGNRegeneron Pharmaceuticals0.094.733.95VRTXVertex Pharmaceuticals0.012.692.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%EDITEditas Medicine71.90%NTLAIntellia Therapeutics88.77%NVSNovartis13.12%REGNRegeneron Pharmaceuticals83.31%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.30%EDITEditas Medicine2.10%NTLAIntellia Therapeutics3.10%NVSNovartis0.01%REGNRegeneron Pharmaceuticals7.02%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics47386.36 million82.26 millionOptionableEDITEditas Medicine23083.71 million80.98 millionOptionableNTLAIntellia Therapeutics600103.58 million98.59 millionOptionableNVSNovartis101,7002.11 billion2.04 billionOptionableREGNRegeneron Pharmaceuticals11,900107.97 million101.15 millionOptionableVRTXVertex Pharmaceuticals4,800256.80 million256.28 millionOptionableEDIT, NTLA, VRTX, CRSP, NVS, and REGN HeadlinesRecent News About These CompaniesAries Wealth Management Buys New Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 16 at 4:40 AM | marketbeat.comOptas LLC Has $864,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 15 at 8:31 AM | marketbeat.comBrighton Jones LLC Purchases 1,994 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 15 at 8:00 AM | marketbeat.comFoster Victor Wealth Advisors LLC Sells 1,664 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 15 at 7:05 AM | marketbeat.comMassachusetts Wealth Management Invests $289,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 15 at 6:56 AM | marketbeat.com3 Monster Stocks to Confidently Own for the Next 10 YearsJune 15 at 5:45 AM | 247wallst.comVertex Pharmaceuticals' SWOT analysis: stock poised for growth amid pipeline expansionJune 14 at 4:36 PM | investing.comStanley Laman Group Ltd. Buys New Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 14 at 5:28 AM | marketbeat.comVertex Pharmaceuticals (VRTX) Stock Moves -1.00%: What You Should KnowJune 13 at 8:55 PM | msn.comOpinicus Capital Inc. Buys Shares of 819 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 13 at 8:51 AM | marketbeat.comCCM Investment Advisers LLC Boosts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 13 at 8:50 AM | marketbeat.comEverhart Financial Group Inc. Has $1.07 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 13 at 8:23 AM | marketbeat.comRMR Wealth Builders Raises Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 13 at 6:54 AM | marketbeat.comFerguson Wellman Capital Management Inc. Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 13 at 5:44 AM | marketbeat.comZhang Financial LLC Trims Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 13 at 4:56 AM | marketbeat.comIntegrated Advisors Network LLC Decreases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 13 at 4:34 AM | marketbeat.comCompagnie Lombard Odier SCmA Purchases 3,000 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 12, 2025 | marketbeat.comGreenwood Capital Associates LLC Sells 6,572 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 12, 2025 | marketbeat.comSimon Quick Advisors LLC Has $1.42 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 12, 2025 | marketbeat.comSG Americas Securities LLC Raises Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 12, 2025 | marketbeat.comSimplicity Wealth LLC Acquires 581 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAlphabet Stock Lags—But Waymo May Be Its Hidden DriverBy Gabriel Osorio-Mazilli | May 25, 2025View Alphabet Stock Lags—But Waymo May Be Its Hidden DriverEDIT, NTLA, VRTX, CRSP, NVS, and REGN Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$41.51 +0.15 (+0.37%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Editas Medicine NASDAQ:EDIT$2.12 +0.15 (+7.61%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Intellia Therapeutics NASDAQ:NTLA$8.88 +0.57 (+6.86%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Novartis NYSE:NVS$118.53 -0.92 (-0.77%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Regeneron Pharmaceuticals NASDAQ:REGN$531.09 +1.85 (+0.35%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Vertex Pharmaceuticals NASDAQ:VRTX$450.37 -5.08 (-1.12%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? 3 Stocks With Rising Dividends Investors Shouldn’t Ignore SoundHound’s AI Growth Story Is Just Getting Started MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
